Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR
MS Cicek, DV Conti, A Curran, PJ Neville… - The …, 2004 - Wiley Online Library
BACKGROUND The prostate is an androgen‐regulated organ and polymorphisms in genes
involved in testosterone synthesis, in particular, SRD5A2 (A49T and V89L variants), CYP17 …
involved in testosterone synthesis, in particular, SRD5A2 (A49T and V89L variants), CYP17 …
MP37-02 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN …
Z Wang*, T Deng, X Lin, S Wu, Z Zhang… - The Journal of …, 2020 - auajournals.org
INTRODUCTION AND OBJECTIVE: Steroid 5-alpha reductase (SRD5A2) is a critical
enzyme for prostatic development and growth. We have found that epigenetic modifications …
enzyme for prostatic development and growth. We have found that epigenetic modifications …
SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
WCY Wang ChunYang, TWY Tao WeiYang… - 2010 - cabidigitallibrary.org
BACKGROUND-Increasing studies investigating the association between steroid 5-alpha
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned
CL Pearce, DJ Van Den Berg… - Human molecular …, 2008 - academic.oup.com
The steroid 5-alpha reductase type II gene (SRD5A2) encodes the enzyme which converts
testosterone (T) to the more active androgen dihydrotestosterone. A non-synonymous single …
testosterone (T) to the more active androgen dihydrotestosterone. A non-synonymous single …
Association of SRD5A2 Genotype and Pathological Characteristics of Prostate Tumors
JM Jaffe, SB Malkowicz, AH Walker, S MacBride… - Cancer research, 2000 - AACR
The enzyme product of SRD5A2, 5α-reductase type II, is responsible for converting
testosterone to the more metabolically active dihydrotestosterone. Therefore, SRD5A2 may …
testosterone to the more metabolically active dihydrotestosterone. Therefore, SRD5A2 may …
Polymorphic markers in the 5α‐reductase type II gene and the incidence of prostate cancer
N Lamharzi, MM Johnson, G Goodman… - … journal of cancer, 2003 - Wiley Online Library
In the prostate, the enzyme encoded by the SRD5A2 gene (5α‐reductase) converts
testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a …
testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a …
SRD5A2 Gene Polymorphisms and the Risk of Prostate Cancer: A Meta-Analysis
C Ntais, A Polycarpou, JPA Ioannidis - Cancer Epidemiology Biomarkers & …, 2003 - AACR
Several polymorphisms in the 5α-reductase type 2 (SRD5A2) gene have been implicated as
risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) …
risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) …
Epigenetic silencing and variable expression of SRD5A2 in specific compartments of human prostate.
38 Background: The steroid-5α reductase type 2 gene (SRD5A2) and protein play a
significant role in the development and growth of prostate tissue. SRD5A2 can be expressed …
significant role in the development and growth of prostate tissue. SRD5A2 can be expressed …
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
Z Wang, T Deng, X Long, X Lin, S Wu, H Wang, R Ge… - Plos one, 2020 - journals.plos.org
Purpose To determine whether SRD5A2 promoter methylation is associated with cancer
progression during androgen deprivation therapy (ADT) in CRPC. Patients and methods In a …
progression during androgen deprivation therapy (ADT) in CRPC. Patients and methods In a …